Chimeric antigen receptor-modified T cells derived from defined CD8+ and CD4+ subsets confer superior antitumor reactivity in vivo
Daniel Sommermeyer, Michael Hudecek, Paula L. Kosasih, Tea Gogishvili, David G. Maloney, Cameron J. Turtle, Stanley R. Riddell
Topics & Concepts
Cytotoxic T cellChimeric antigen receptorCD8T cellIn vivoCD19BiologyImmunologyCell therapyAdoptive cell transferAntigenEffectorCancer researchIn vitroCell biologyImmune systemStem cellBiochemistryBiotechnologyCAR-T cell therapy researchNanowire Synthesis and ApplicationsVirus-based gene therapy research